From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|August 2, 2022
Daily Medication Pearl: Omadacycline (Nuzyra)
Author(s)Saro Arakelians, PharmD
Omadacycline (Nuzyra) is indicated for the treatment of adult patients with infections caused by susceptible microorganisms—community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Advertisement
Medication Pearl of the Day: Omadacycline (Nuzyra)
Indication: Omadacycline (Nuzyra) is a tetracycline class antibacterial indicated for the treatment of adult patients with infections caused by susceptible microorganisms—community-acquired bacterial pneumonia (CAPB) and acute bacterial skin and skin structure infections (ABSSSI).
Insight:
- Dosing: The IV loading dose is 200 mg over 60 minutes or 100 mg over 30 minutes twice. The loading dose for tablets is 450 mg orally once daily. The maintenance dosing is 100 mg IV over 30 minutes or 300 mg orally once daily.
- Dosage forms: For injection, 100 mg of omadacycline (equivalent to 131 mg omadacycline tosylate) as a lyophilized powder in a single-dose vial for reconstitution and further dilution before intravenous infusion. For tablets: 150 mg omadacycline.
- Adverse events: The most common adverse reactions (incidence ≥ 2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.
- Mechanism of action: Omadacycline is an aminomethylcycline antibacterial within the tetracycline class of antibacterial drugs. Omadacycline binds to the 30S ribosomal subunit and blocks protein synthesis. Omadacycline is active in vitro against Gram positive bacteria expressing tetracycline resistance active efflux pumps (tetK and tet L) and ribosomal protection proteins (tet M). In general, omadacycline is considered bacteriostatic; however, omadacycline has demonstrated bactericidal activity against some isolates of S pneumoniae and H influenzae.
Source:
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5